In Brief: FDA immunosuppressant drugs subcommittee meeting
FDA immunosuppressant drugs subcommittee meeting: On March 30, the subcommittee of the Antiviral Drugs Committee will discuss Syntex' NDAs for mycophenolate mofetil for prophylaxis of organ rejection and treatment of refractory organ rejection in patients receiving allogenic renal transplants. On March 31, the subcommittee will evaluate NDAs for Sandoz' cyclosporine microemulsion for prophylaxis of organ rejection in kidney, liver and heart allogenic transplants. The meeting will be held at the Silver Spring, Md. Holiday Inn, Plaza Ballroom, from 8 a.m.-6 p.m. on the first day and from 8 a.m.-2 p.m. on the second...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth